Korean Journal of Clinical Laboratory Science (대한임상검사과학회지)

Korean Society for Clinical Laboratory Science (대한임상검사과학회)
권호 표지
DOI QR코드

DOI QR Code

The Patterns of Conversion to Anti-Tuberculosis Drug Resistance in Mycobacterium tuberculosis

결핵균의 항결핵제 내성 전환 패턴

  • Chong, Moo-Sang (Department of Clinical Laboratory Science, Cheju Halla University) ;
  • Lee, Kyutaeg (Department of Laboratory Medicine, Green Cross Laboratories)
  • 정무상 (제주한라대학교 임상병리과) ;
  • 이규택 (녹십자의료재단 진단검사의학과)
  • Received : 2022.04.29
  • Accepted : 2022.05.22
  • Published : 2022.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

The prevalence of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) are increasing. We analyzed the patterns of drug resistance and tracking period days of acquiring anti-mycobacterial resistance. From January 2010 to December 2019, drug susceptibility tests (DST) were performed by the absolute concentration method using the Löwenstein-Jensen solid medium and pyrazinamidase activity test (to assess pyrazinamide resistance) in samples from patients who were referred to the Green Cross Laboratories in Yongin. Among the cases that showed resistance to one or more anti-tuberculosis drugs, 55 patients (33.1%) were resistant to isoniazid (INH) at the time of initial referral, and the rates for the development of resistant anti-tuberculosis drugs were ethambutol (EMB) (26.6%), rifampicin (RFP) (21.9%), quinolones (QUI) (21.9%) and pyrazinamide (PZA) (10.9%), in that order. In the cases sensitive to all 10 anti-tuberculosis drugs initially, the development of resistance to INH was the most frequent, seen in 43 patients (7.2%). The average follow-up period was 435.6 days, and the resistance development was observed in the order of INH (7.2%), RFP (3.9%), SM (1.9%), QUI (0.7%), amikacin (AMK) (0.5%), and EMB (0.5%). The conversion of susceptible strains to resistant strains is an important warning sign for the patient, especially in cases of conversion to MDR or XDR. This information would be helpful for improving patient care during TB treatment.

다제내성결핵과 광범위내성결핵은 결핵 치료의 문제가 되고 있으며 발생빈도 역시 증가하고 있다. 본 연구는 2010년 1월부터 2019년 12월까지 녹십자의료재단 의뢰된 환자를 대상으로 Löwenstein-Jensen 고체배지와 pyrazinamide for pyrazinamidase를 이용하여 약물감수성시험(DST)을 시행하여 내성으로 전환되는 항결핵제 패턴과 평균 추적 기간을 분석하였다. 항결핵제 중 1개 이상의 항결핵제 내성을 보인 증례들에서 초기 의뢰 시 INH 항결핵제에 내성인 경우가 55명(33.1%)으로 가장 높은 비율로 나타났으며, 내성으로 전환된 항결핵제는 EMB 17명(26.6%), RFP 14명(21.9%), QUI 14명(21.9%), PZA 12명(10.9%) 순으로 조사되었다. 10개의 항결핵제에 모두 감수성인 증례들에서는 INH 항결핵제에 대한 내성 전환은 43명(7.2%)으로 가장 빈도가 높았으며, 평균 추적 기간은435.6일로 조사되었으며, 내성으로 전환되는 항결핵제의 내성전환율은 INH 43명(7.2%), RFP 23명(3.9%), SM 11명(1.9%), QUI 4명(0.7%), AMK 3명(0.5%), EMB 3명(0.5%)이었다. 이에 본 연구는 항결핵제에 대한 감수성에서 내성으로의 전환은 특히 다제내성결핵과 광범위 내성결핵의 전환되는 환자에게 매우 중요한 자료가 될 것으로 보이며, 결핵 치료에서 환자 치료에 도움이 될 것으로 사료된다.

Keywords

References

  1. GBD Tuberculosis Collaborators. The global burden of tuberculosis: results from the Global Burden of Disease Study 2015. Lancet Infect Dis. 2018;18:261-284. https://doi.org/10.1016/S1473-3099(17)30703-X
  2. Korea Centers for Disease Control and Prevention. Annual report on the notified tuberculosis patients in Korea 2019. Seoul: Korea Centers for Disease Control and Prevention; 2020. p35-41.
  3. Korea Centers for Disease Control and Prevention. Korean guidelines for tuberculosis (4th edition). Seoul: Korea Centers for Disease Control and Prevention; 2020. p16-59.
  4. Pablos-Mendez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F, et al. Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against tuberculosis and lung disease working group on anti-tuberculosis drug resistance surveillance. N Engl J Med. 1998;338:1641-1649. http://doi.org/10.1056/NEJM199806043382301
  5. Centers for Disease Control and Prevention (CDC). Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs--worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep. 2006;55:301-305. https://doi.org/10.1037/e566482006-002
  6. Velayati AA, Masjedi MR, Farnia P, Tabarsi P, Ghanavi J, Ziazarifi AH, et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran. Chest. 2009;136:420-425. https://doi.org/10.1378/chest.08-2427
  7. Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim SJ, Reniero A, et al. Global trends in resistance to antituberculosis drugs. World Health Organization-International union against tuberculosis and lung disease working group on anti-tuberculosis drug resistance surveillance. N Engl J Med. 2001;344:1294-1303. http://doi.org/10.1056/NEJM200104263441706
  8. Mitchison DA. Drug resistance in tuberculosis. Eur Respir J. 2005;25:376-379. https://doi.org/10.1183/09031936.05.00075704
  9. World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis. Geneva. World Health Organization; 2016.
  10. Lee KT, Chong MS. The patterns of acquiring anti-mycobacterial drug resistance by susceptible strains of Mycobacterium tuberculosis. Korean J Clin Lab Sci. 2021;53:137-142. https://doi.org/10.15324/kjcls.2021.53.2.137
  11. Son EJ, Jeon DS. Current situation of tuberculosis and national strategic plan for tuberculosis control in Korea. J Korean Med Assoc. 2021;64:316-323. http://doi.org/10.5124/jkma.2021.64.4.316
  12. Kim DH, Kim HJ, Park SK, Kong SJ, Kim YS, Kim TH. et al. Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis. Am J Respir Crit Care Med. 2008;178:1075-1082. https://doi.org/10.1164/rccm.200801-132OC
  13. World Health Organizaton. Guidelines for the programmatic management of drug-resistant tuberulosis. Emergency update 2008. Geneva.World Health Organization; 2008.
  14. Joint Committee for the Development of Korean Guideline for Tuberculosis; Korean Centers for Disease Control and Prevention. Korean guidelines for tuberculosis. 1st ed. Cheongwon: Korea Centers for Disease Control and Prevention; 2011.
  15. Kang YA. Diagnosis and treatment of multidrug-resistant tuberculosis. J Korean Med Assoc. 2014;57:27-33. http://doi.org/10.5124/jkma.2014.57.1.27
  16. Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010;182:684-692. https://doi.org/10.1164/rccm.201001-0077OC
  17. Kim BJ, Lee IH, Lee DH, Bai GH, Kong SJ, Lee SH, et al. The Current Status of Multidrug-resistant Tuberculosis in Korea. Tuberc Respir Dis. 2006;60:404-411. https://doi.org/10.4046/trd.2006.60.4.404
  18. World Health Organization. Global tuberculosis report 2018. Geneva. World Health Organization; 2018.